Reply Diagnosis and Treatment of Obstructive Sleep Apnea Is Key to Achieving Optimal Results After Catheter Ablation of Atrial Fibrillation by Fein, Adam S. et al.
Correspondence JACC Vol. 63, No. 6, 2014
February 18, 2014:605–9
608REFERENCES
1. Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea
reduces the risk of atrial ﬁbrillation recurrence after catheter ablation.
J Am Coll Cardiol 2013;62:300–5.
2. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-
disordered breathing among middle-aged adults. N Engl J Med 1993;
328:1230–5.
3. Albuquerque FN, Calvin AD, Sert Kunioshi FH, et al. Sleep-disordered
breathing and excessive daytime sleepiness in patients with atrial ﬁbril-
lation. Chest 2011;141:967–73.
4. Chan KH, Wilcox I. Obstructive sleep apnea: a novel trigger for cardiac
arrhythmias and potential therapeutic target. Expert Rev Cardiovasc
Ther 2010;8:981–94.
5. Dimitri H, Ng M, Brooks AG, et al. Atrial remodeling in obstructive
sleep apnea: implications for atrial ﬁbrillation. Heart Rhythm 2012;9:
321–7.
6. Wilcox I, Semsarian C. Obstructive sleep apnea: a respiratory syndrome
with protean cardiovascular manifestations. J Am Coll Cardiol 2009;54:
1810–1.ReplyDiagnosis and Treatment of Obstructive
Sleep Apnea Is Key to Achieving Optimal
Results After Catheter Ablation of
Atrial FibrillationThe association between obstructive sleep apnea (OSA) and car-
diovascular morbidity is well established (1,2). In particular, OSA
has been shown to potentiate atrial ﬁbrillation (AF) substrate in
both animal and human studies (3–7). Our study not only de-
monstrated that OSA adversely affects the results of AF ablation,
but also highlighted the beneﬁcial effect of OSA treatment on
AF ablation outcome in this patient population (8).
Wilcox and colleagues have articulately argued that OSA is
an underdiagnosed disease, likely to coexist in a signiﬁcant pro-
portion of patients with AF. They drew our attention to the current
framework with which we deﬁne OSA and subsequently use to
screen patients. We agree that the current criteria overemphasize
respiratory symptomatology and daytime somnolence, which may
affect a minority of patients with OSA (9–11). The traditional focus
on these symptoms oversimpliﬁes the clinical proﬁle of patients with
sleep apnea and thus underestimates its pronounced cardiovascular
impact, which may be the heralding symptom.
Threshold criteria for OSA testing in patients with AF should
probably be lowered, considering the higher pre-test probability
in this patient population. Until new criteria are formalized, we
should promote awareness of the association between OSA and
AF. Not only is timely identiﬁcation of OSA in AF patients
important in optimizing AF management, but it may mitigate
other deleterious cardiovascular effects.Adam S. Fein, MD
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2008;31:1071–8.Effect of Ivabradine on
Heart Failure With
Preserved Ejection FractionWe read with great interest the paper by Kosmala et al. (1) in which
they report the increased exercise capacity associated with an im-
proved left ventricular (LV) ﬁlling pressure in patients with heart
failure with preserved ejection fraction (HFpEF) treated with
ivabradine. In addition to the mechanisms elegantly discussed by the
authors, we would like to point out other potential important con-
tributors to the observed effect.
Heart rate (HR) is one of the major diastolic function de-
terminants. Indeed, an increase in HR may shorten the diastole
duration, precluding myocardial relaxation from being complete,
and resulting in increased ﬁlling pressures. This may be particularly
